BOSTON, August 04, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, ...
Vertex Pharmaceuticals’VRTX2.65%increase; green up pointing triangle stock fell in post-market trading Monday, after the company said it would not progress a next-generation pain treatment into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback